Results 171 to 180 of about 5,926 (192)

Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials

Journal of Clinical Pharmacology, 2020
Mohamed Elmeliegy, Yanke Yu, Jennifer K Litton   +2 more
exaly  

Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial

Journal of Clinical Pharmacology, 2020
Yanke Yu, Mohamed Elmeliegy, Jennifer K Litton   +2 more
exaly  

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Case Medical Research, 2019
openaire   +1 more source

<p>Evidence to date: talazoparib in the treatment of breast cancer</p>

OncoTargets and Therapy, 2019
Pedro Exman, Romualdo Barroso-Sousa, Sara M Tolaney   +2 more
exaly  

Olaparib/talazoparib

Reactions Weekly
openaire   +1 more source

Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer

Journal of Clinical Pharmacology, 2020
Yanke Yu, Haihong Shi, Diane D Wang
exaly  

Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

Pediatric Blood and Cancer, 2020
Eric S Schafer, Rachel E Rau, Stacey L Berg   +2 more
exaly  

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

European Journal of Cancer, 2018
Sara A Hurvitz, N C Turner, M L Telli
exaly  

Talazoparib and Thoracic RT for ES-SCLC

Case Medical Research, 2019
openaire   +1 more source

Talazoparib for BRCA-mutated advanced breast cancer

The Lancet Oncology, 2018
openaire   +1 more source